Contrasting Pervasip (OTCMKTS:PVSP) & MediWound (NASDAQ:MDWD)

Pervasip (OTCMKTS:PVSP) and MediWound (NASDAQ:MDWD) are both small-cap utilities companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Valuation & Earnings

This table compares Pervasip and MediWound’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pervasip	$15.77 million	0.14	-$2.35 million	N/A	N/A
MediWound	$18.69 million	7.39	-$6.72 million	($1.38)	-10.78

Pervasip has higher earnings, but lower revenue than MediWound.

Analyst Recommendations

This is a breakdown of recent recommendations for Pervasip and MediWound, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pervasip	0	0	0	0	N/A
MediWound	0	0	2	0	3.00

MediWound has a consensus target price of $32.00, indicating a potential upside of 115.05%. Given MediWound’s higher probable upside, analysts clearly believe MediWound is more favorable than Pervasip.

Institutional and Insider Ownership

46.8% of MediWound shares are owned by institutional investors. 9.2% of Pervasip shares are owned by company insiders. Comparatively, 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Pervasip has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, MediWound has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Profitability

This table compares Pervasip and MediWound’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pervasip	-15.67%	N/A	-21.75%
MediWound	-64.24%	-21.67%	-10.23%

Summary

MediWound beats Pervasip on 7 of the 10 factors compared between the two stocks.

About Pervasip

Pervasip Corporation focuses on developing cloud-based applications to monitor and control greenhouse facilities. It intends to develop and deliver products and technologies to agricultural markets; develop scientific methods for the analysis of cannabinoids in flowers, concentrates, and edibles; and assist medical marijuana specialty production facilities to regulate, calculate proper dosage, and understand the importance of consistency in product. The company was formerly known as eLEC Communications Corp. and changed its name to Pervasip Corp. in December 2007. Pervasip Corp. was founded in 1964 and is based in White Plains, New York.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.